My primary responsibility as a thoracic oncologist at Memorial Sloan Kettering is to care for patients with lung cancer and malignant pleural mesothelioma. I also run clinical trials that test novel drugs and treatment strategies for individuals with small cell lung cancer and mesothelioma.
I have a particular interest in therapies that boost the immune system to allow it to recognize and attack specific molecules on cancer cells. I have conducted studies testing cancer vaccines developed by scientists at our center in patients with small cell lung cancer and mesothelioma.
As director of Memorial Sloan Kettering’s Mesothelioma Program, I head a multidisciplinary team of physicians and scientists dedicated to developing better treatment for the disease. Our group has led studies exploring the benefit of chemotherapy, surgery, and radiation for patients with early-stage mesothelioma. I have also led an international phase III trial of vorinostat for patients with mesothelioma who had previously been treated with chemotherapy.
I also direct the committee that establishes the National Comprehensive Cancer Network guidelines for the management of mesothelioma, and I serve as Chair of the Science Advisory Board for the Mesothelioma Applied Research Foundation.
In addition, I am co-director of Memorial Sloan Kettering’s Medical Oncology/Hematology Fellowship Training Program.
- Clinical Expertise: Mesothelioma; Small Cell Lung Cancer and Other Pulmonary Neuroendocrine Tumors; Non-Small Cell Lung Cancer
- Languages Spoken: English
- Education: MD, Washington University School of Medicine in St. Louis
- Residencies: The Johns Hopkins Hospital
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Lee M. Krug
Clinical Trials Co-Investigated by Lee M. Krug
- A Phase I Study of GL-ONC1 for Treating Malignant Pleural Effusion
- A Phase I Study of LDE225 with Etoposide and Cisplatin for the Initial Treatment of Extensive Small Cell Lung Cancer
- A Phase I Study of LY3023414 in Patients with Advanced Cancer
- A Phase I Study of VS-5584 plus VS-6063 in Patients with Relapsed Malignant Mesothelioma
- A Phase I/II Study of SC16LD6.5 in Patients with Recurrent Small Cell Lung Cancer
- A Phase Ib/II Study of OMP-59R5 plus Etoposide and Cisplatin in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer
- A Phase II Study of Temozolomide Alone or with ABT-888 (Veliparib) in Patients with Relapsed or Refractory Small Cell Lung Cancer
- A Phase II Study of VS-6063 in Patients with Malignant Pleural Mesothelioma